The IBTS had also established a weekly review meeting with the provider, “and while the HSE is not attending, it is proving useful to manage the issues as they arise”, it was stated. The IBTS Board agreed that if the HSE did not sign the SLA within a week, the matter would be escalated to Tony O’Brien, Director General, HSE, and to Dr Philip Crowley, Director for Patient Safety and Quality, HSE. The IBTS had drafted a Service Level Agreement (SLA) with the Executive, “clarifying roles and responsibilities regarding the transport and distribution of product”, but the HSE “declined” to sign this. The three variables are detailed and examined in the case of. The contract with the provider “is a HSE contract, not an IBTS contract”, noted the minutes. These are intra-industry trade (IIT), foreign direct investment (FDI) and intrafirm trade (IFT). Minutes from the Transfusion Service’s Board meeting in June, under the Chief Executive’s report, revealed that the IBTS had needed to emphasise to the contractor “the absolute requirement” of maintaining the “integrity” of the transport of the products.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |